Clinical trialNCT07388524RecruitingPhase 3Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

SponsorNational Cancer Institute (NCI)Enrollment336Lung Non-Small Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Muhammad Furqan
Alliance for Clinical Trials in Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

49 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beebe South Coastal Health Campus
Millville, Delaware, United States
Gregory A. Masters
Recruiting
Helen F Graham Cancer Center
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Medical Oncology Hematology Consultants Pa
Newark, Delaware, United States
Gregory A. Masters
Recruiting
Beebe Health Campus
Rehoboth Beach, Delaware, United States
Gregory A. Masters
Recruiting
Kootenai Health - Coeur D'Alene
Coeur d'Alene, Idaho, United States
John M. Schallenkamp
Recruiting
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho, United States
John M. Schallenkamp
Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho, United States
John M. Schallenkamp
Recruiting
Illinois Cancercare-Bloomington
Bloomington, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Canton
Canton, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Carthage
Carthage, Illinois, United States
Bryan A. Faller
Recruiting
Carle at the Riverfront
Danville, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Decatur Memorial Hospital
Decatur, Illinois, United States
Bryan A. Faller
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Illinois Cancercare-Eureka
Eureka, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Galesburg
Galesburg, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Kewanee Clinic
Kewanee, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Macomb
Macomb, Illinois, United States
Bryan A. Faller
Recruiting
Carle Physician Group-Mattoon/charleston
Mattoon, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Carle Bromenn Medical Center
Normal, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Carle Cancer Institute Normal
Normal, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Cancer Care Center of O'Fallon
O'Fallon, Illinois, United States
Bryan A. Faller
Recruiting
Hshs Saint Elizabeth'S Hospital
O'Fallon, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Ottawa Clinic
Ottawa, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Pekin
Pekin, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Peoria
Peoria, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Peru
Peru, Illinois, United States
Bryan A. Faller
Recruiting
Illinois Cancercare-Princeton
Princeton, Illinois, United States
Bryan A. Faller
Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Springfield Clinic
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Springfield Memorial Hospital
Springfield, Illinois, United States
Bryan A. Faller
Recruiting
Carle Cancer Center
Urbana, Illinois, United States
Vamsi K. Vasireddy
Recruiting
Illinois Cancercare - Washington
Washington, Illinois, United States
Bryan A. Faller
Recruiting
Mary Greeley Medical Center
Ames, Iowa, United States
Joseph J. Merchant
Recruiting
Mcfarland Clinic - Ames
Ames, Iowa, United States
Joseph J. Merchant
Recruiting
Mercy Hospital
Cedar Rapids, Iowa, United States
Deborah W. Wilbur
Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, United States
Deborah W. Wilbur
Recruiting
Mcfarland Clinic - Trinity Cancer Center
Fort Dodge, Iowa, United States
Joseph J. Merchant
Recruiting
Mcfarland Clinic - Marshalltown
Marshalltown, Iowa, United States
Joseph J. Merchant
Recruiting
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, United States
Jewraj G. Maheshwari
Recruiting

9 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Atezolizumab and Recombinant Human Hyaluronidase

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Mar 2027
Primary completion: 30 Sept 2032
Completion: 30 Sept 2032
Last update posted: 20 Aug 2026
Registered enrollment: 336
Registry id: NCT07388524

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.